Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eargo, Inc. stock logo
EAR
Eargo
$70.50
$52.85
$1.47
$8.48
$1.46B1.523,347 shsN/A
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
Phreesia, Inc. stock logo
PHR
Phreesia
$20.74
-0.5%
$23.43
$12.05
$34.98
$1.17B0.92514,996 shs365,741 shs
Verona Pharma plc stock logo
VRNA
Verona Pharma
$15.45
-0.7%
$16.27
$11.83
$23.81
$1.25B0.41489,194 shs294,733 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eargo, Inc. stock logo
EAR
Eargo
0.00%0.00%0.00%+2,590.84%+1,258.38%
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%+2.67%
Phreesia, Inc. stock logo
PHR
Phreesia
-0.41%-10.33%-13.33%-18.73%-35.71%
Verona Pharma plc stock logo
VRNA
Verona Pharma
-0.71%-0.90%-3.98%-15.80%-25.43%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eargo, Inc. stock logo
EAR
Eargo
N/AN/AN/AN/AN/AN/AN/AN/A
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
Phreesia, Inc. stock logo
PHR
Phreesia
4.5294 of 5 stars
4.42.00.04.22.72.50.6
Verona Pharma plc stock logo
VRNA
Verona Pharma
2.1543 of 5 stars
3.52.00.00.02.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eargo, Inc. stock logo
EAR
Eargo
N/AN/AN/AN/A
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/A
Phreesia, Inc. stock logo
PHR
Phreesia
2.86
Moderate Buy$31.6252.44% Upside
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.00
Buy$33.60117.48% Upside

Current Analyst Ratings

Latest HSKA, EAR, VRNA, and PHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Verona Pharma plc stock logo
VRNA
Verona Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.00
3/22/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$28.00
3/21/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$23.00
3/21/2024
Phreesia, Inc. stock logo
PHR
Phreesia
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$28.00 ➝ $30.00
3/18/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $31.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $37.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$32.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$25.00 ➝ $30.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $23.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eargo, Inc. stock logo
EAR
Eargo
$41.11M35.61N/AN/A$4.87 per share14.48
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
Phreesia, Inc. stock logo
PHR
Phreesia
$356.30M3.28N/AN/A$4.52 per share4.59
Verona Pharma plc stock logo
VRNA
Verona Pharma
$460K2,714.50N/AN/A$3.10 per share4.98

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eargo, Inc. stock logo
EAR
Eargo
-$157.49M-$7.52N/AN/A-263.14%-135.08%-96.37%N/A
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
Phreesia, Inc. stock logo
PHR
Phreesia
-$136.88M-$2.52N/AN/AN/A-38.42%-53.33%-38.04%5/30/2024 (Confirmed)
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/9/2024 (Confirmed)

Latest HSKA, EAR, VRNA, and PHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2024N/A
Phreesia, Inc. stock logo
PHR
Phreesia
-$0.51N/A+$0.51N/AN/AN/A  
5/9/2024N/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.24N/A+$0.24N/AN/AN/A  
3/14/2024Q4 2024
Phreesia, Inc. stock logo
PHR
Phreesia
-$0.58-$0.56+$0.02-$0.56$93.52 million$95.00 million    
2/29/2024Q4 2023
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.23-$0.16+$0.07-$0.16N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eargo, Inc. stock logo
EAR
Eargo
N/AN/AN/AN/AN/A
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
Phreesia, Inc. stock logo
PHR
Phreesia
N/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eargo, Inc. stock logo
EAR
Eargo
N/A
3.22
2.97
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
Phreesia, Inc. stock logo
PHR
Phreesia
0.02
1.78
1.78
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.20
33.33
33.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Eargo, Inc. stock logo
EAR
Eargo
80.53%
Heska Co. stock logo
HSKA
Heska
99.01%
Phreesia, Inc. stock logo
PHR
Phreesia
92.10%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%

Insider Ownership

CompanyInsider Ownership
Eargo, Inc. stock logo
EAR
Eargo
0.81%
Heska Co. stock logo
HSKA
Heska
12.30%
Phreesia, Inc. stock logo
PHR
Phreesia
5.80%
Verona Pharma plc stock logo
VRNA
Verona Pharma
4.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Eargo, Inc. stock logo
EAR
Eargo
24320.76 million20.59 millionNot Optionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
Phreesia, Inc. stock logo
PHR
Phreesia
1,43856.39 million53.12 millionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
7980.82 million76.94 millionOptionable

HSKA, EAR, VRNA, and PHR Headlines

SourceHeadline
Verona Pharma plc (NASDAQ:VRNA) is Vivo Capital LLCs 6th Largest PositionVerona Pharma plc (NASDAQ:VRNA) is Vivo Capital LLC's 6th Largest Position
marketbeat.com - April 27 at 9:40 PM
Jennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA)Jennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA)
marketbeat.com - April 25 at 7:26 AM
Verona Pharma shares target raised on COPD launch outlookVerona Pharma shares target raised on COPD launch outlook
investing.com - April 25 at 3:40 AM
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
globenewswire.com - April 25 at 2:00 AM
Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrade
marketbeat.com - April 16 at 10:36 AM
Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper SandlerVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandler
marketbeat.com - April 16 at 8:33 AM
Verona Pharma (NASDAQ:VRNA) Shares Up 4.9%Verona Pharma (NASDAQ:VRNA) Shares Up 4.9%
marketbeat.com - April 4 at 3:08 PM
VRNA Apr 2024 17.500 callVRNA Apr 2024 17.500 call
finance.yahoo.com - March 16 at 8:32 AM
VRNA Apr 2024 15.000 callVRNA Apr 2024 15.000 call
finance.yahoo.com - March 16 at 3:31 AM
Andrew Fisher Joins Verona Pharma as General CounselAndrew Fisher Joins Verona Pharma as General Counsel
globenewswire.com - March 4 at 2:00 AM
Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D PipelineBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline
markets.businessinsider.com - March 1 at 1:10 PM
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call TranscriptVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 1:10 PM
3 Healthcare Stocks That Have Outperformed Nvidia Since 20223 Healthcare Stocks That Have Outperformed Nvidia Since 2022
fool.com - March 1 at 8:45 AM
Verona Pharma plc 2023 Q4 - Results - Earnings Call PresentationVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 29 at 11:18 AM
Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - February 29 at 10:48 AM
Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial ResultsVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results
finance.yahoo.com - February 29 at 10:48 AM
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - February 29 at 2:00 AM
Verona Pharma earnings preview: what to expectVerona Pharma earnings preview: what to expect
markets.businessinsider.com - February 28 at 1:35 PM
When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?
finance.yahoo.com - February 25 at 12:52 PM
Verona Pharma PLC ADRVerona Pharma PLC ADR
wsj.com - February 25 at 7:52 AM
VRNA Mar 2024 15.000 putVRNA Mar 2024 15.000 put
finance.yahoo.com - February 17 at 7:46 PM
VRNA Jun 2024 30.000 callVRNA Jun 2024 30.000 call
finance.yahoo.com - February 17 at 2:46 PM
Verona Pharma: A Few Points From The Bull And Bear CaseVerona Pharma: A Few Points From The Bull And Bear Case
seekingalpha.com - February 15 at 5:55 PM
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
finance.yahoo.com - February 15 at 10:20 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Eargo logo

Eargo

NASDAQ:EAR
Eargo, Inc., a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States. It markets and sells hearing aids. The company sells its products direct-to-consumer and through omni-channel. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was incorporated in 2010 and is headquartered in San Jose, California.
Heska logo

Heska

NASDAQ:HSKA
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Phreesia logo

Phreesia

NYSE:PHR
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
Verona Pharma logo

Verona Pharma

NASDAQ:VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.